Spero Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Spero Therapeutics's estimated annual revenue is currently $17.4M per year.
- Spero Therapeutics's estimated revenue per employee is $272,188
- Spero Therapeutics's total funding is $434.6M.
- Spero Therapeutics's current valuation is $426.7M. (January 2022)
Employee Data
- Spero Therapeutics has 64 Employees.
- Spero Therapeutics grew their employee count by 7% last year.
Spero Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer and Chief Business Officer | Reveal Email/Phone |
2 | Head, Enterprise and People Technology | Reveal Email/Phone |
3 | VP, Alliance Management and Business Development | Reveal Email/Phone |
4 | SVP, Clinical Development | Reveal Email/Phone |
5 | VP, Head Clinical Microbiology | Reveal Email/Phone |
6 | VP, Corporate Affairs | Reveal Email/Phone |
7 | SVP, Financial Planning and Analysis | Reveal Email/Phone |
8 | VP, Clinical Development | Reveal Email/Phone |
9 | VP, Head Clincal Operations | Reveal Email/Phone |
10 | Director, Clinical Operations | Reveal Email/Phone |
Spero Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Spero Therapeutics?
Spero Therapeutics aims to be the premier company developing novel therapies to treat highly resistant bacterial infections. The culture at Spero is one of respect, action, collaboration and transparency. Spero team members are leaders in the field, and have the ability and desire to be a part of a team. At Spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
keywords:N/A
$434.6M
Total Funding
64
Number of Employees
$17.4M
Revenue (est)
7%
Employee Growth %
$426.7M
Valuation
N/A
Accelerator
Spero Therapeutics News
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four...
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England...
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financing agreement with ...
CAMBRIDGE, Mass. - Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced that on J ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 64 | 0% | N/A |
#2 | $21.2M | 64 | -36% | $85M |
#3 | $8.1M | 64 | -22% | N/A |
#4 | $15.6M | 64 | -9% | N/A |
#5 | $8.4M | 64 | 8% | N/A |